
Pediatric hematologist | Associate Professor @univamu and @aphm_actu #PHOdocs #pediatrics #hematology #oncology #immunology #pedonc #pedcsm #childhoodcancer
Marseille, France
Joined July 2017
- Tweets74
- Following515
- Followers234
- Likes71
Paul Saultier, MD, PhD retweeted
Le @CRPP12 et l'@AFH_Officiel organisent le 1er weekend d'éducation thérapeutique du patient 100% pathologies plaquettaires!
📍Strasbourg
📅19 et 20 novembre 2022.
Pour vous inscrire: fr.surveymonkey.com/r/WEPPST…
Plus d'infos: maladies-plaquettes.org/even… et afh.asso.fr/2022/09/28/parti…
Our group @aphm_actu and @univamu published a randomized trial of a physical activity program for children with cancer. Benefits : exercise capacity, self-esteem, quality of life.
🙏 share and help children and adolescents with cancer #keepmoving.
#Sport #ChildhoodCancer #QoL
Paul Saultier, MD, PhD retweeted
Proud to share our work on #PAX5 #germline mutations 🧬and susceptibility to acute lymphoblastic #leukemia🔬
@BloodJournal pubmed.ncbi.nlm.nih.gov/3303…
👉A collaborative work @CHU_Lille @univ_lille @Canther_Lille @crctoncopole w/ Laura Jamrog, Claude Preudhomme & Cyril Broccardo
Paul Saultier, MD, PhD retweeted
Our study is finally published in @jclinicalinvest!
Anti-leukemic activity in the absence of severe toxicities with nonviral Sleeping Beauty–engineered CAR T cells. Thanks to all our great collaborators.
#Immunotherapy #tcells #GeneTherapy
jci.org/articles/view/138473
Paul Saultier, MD, PhD retweeted
Novel mechanism of FLT3 activation in BCP-ALL
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking ow.ly/7FKx50B8JPG
How #hemoglobin complex evolved from an ancestral monomer to a modern tetramer ?
Fascinating insights into the evolution of the protein complex mediating respiratory #oxygen transport.
nature.com/articles/s41586-0…
Higher than anticipated frequency of germline RUNX1 mutations among patients with RUNX1-mutated acute myeloid #leukemia. This study suggest specific pathophysiology.
#predisposition @BloodJournal
1
6
I very much enjoyed writing this short review with @SiobhanRice12 on infant leukaemia. @MRC_WIMM @wellcometrust @bloodcancer_uk @BloodCancer_Res authors.elsevier.com/a/1b68e…
1
1
Paul Saultier, MD, PhD retweeted
Just published - Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group ascopubs.org/doi/abs/10.1200…
Paul Saultier, MD, PhD retweeted
(Examines patient with conjunctivitis)
Brain: Touch your face
Me: What...no...why
Brain: it itches
Me: No it doesn’t, stop
Brain: IT ITCHES
Me: please I beg you
Brain: IT ITC̸͈̯̩͍͍̞̞̙̭̖̰̊͋̂̋̋̓̀̾̔̀̚Ȟ̶̨̛̻̳͉̪͙̯̹̗̘͜E̷͙̞͓̱͙͈̓̓̔̊̆̓̆ͅS̴̛͖̯͉͇̳̠͈̘̠̈́͐͘͝ͅ
Paul Saultier, MD, PhD retweeted
Pour les cancers de l’enfants ce traitement par CAR-T-Cells est proposé à l’aphm @aphm_actu dans le service d’oncologie de l’hôpital d’enfants timone. Un des rares services français leader en onco pédiatrie a avoir cette autorisation
[Repost] Une très belle avancée cette année : @paoli_calmettes de #Marseille propose un nouveau traitement pour guérir les cancers du sang ! Une véritable révolution 👏 #Santé
Paul Saultier, MD, PhD retweeted
Replying to @psaultier
@psaultier presenting high-level evidence for APA benefits in children with cancer @aphm_actu @SIOPYI_Network #SIOP2019
The specific signature IKZF1-plus associated with very poor prognosis in MRD-positive subgroup. #SIOP2019
Martin Schrappe reminded us how powerful MRD as prognostic marker - even in IKZF1 patients if MRD is negative at End of induction then kids have excellent outcome . If MRD is positive then IKZF1 has very poor prognosis #SIOP2019 @WorldSIOP
Virginie Gandemer reported efficacy data of ruxolitinib in steroid-refractory #GVHD:
- Overall response rate >70%
- Particular interest in gut GVHD?
#ChildhoodCancer #Leukemia #HSCT #SIOP2019
@WorldSIOP @SFGM_TC
Paul Saultier, MD, PhD retweeted
#SIOP2019 Durin: SPINK1 genetic polymorphism maybe a risk factor for ASP associated panreatitis in French kids with ALL
Replying to @GabrielRevon
@GabrielRevon nicely showed that >60% of children and AYA experience high-intensity end-of-life care (associated with decreased #QoL).
“Need for dedicated #PaliativeCare, teams, improved communication with patients/family and funding”.
#ChildhoodCancer
@WorldSIOP @aphm_actu
Paul Saultier, MD, PhD retweeted
Great presentation on patient centered approach in respiratory distress management by F. Craig #SIOP2019


























